✦ LIBER ✦

718 ORAL Results of a phase II study with sunitinib malate (SU11248) in patients (pts) with advanced neuroendocrine tumours (NETs)

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

797 ORAL Sunitinib malate (SU11248) show

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 135 KB

SU11248 (sunitinib malate) therapy in pa

✍ K.D. Miller; Burstein; A.D. Elias; H.S. Rugo; M.A. Cobleigh; A.C. Wolff; P.D. Ei 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 133 KB

7501 ORAL Continuous daily dosing (CDD)

✍ Blay, J.Y.; George, S.; Casali, P.G.; Le Cesne, A.; Morgan, J.A.; Pokela, J.; Qu 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB

6548 POSTER Phase II study of sunitinib

✍ Gervais, R.; Hainsworth, J.D.; Blais, N.; Soria, J.C.; Laskin, J.; Hamm, J.T.; L 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 61 KB

406 POSTER Safety and efficacy of suniti

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 262 KB

A phase II study of interferon alpha-2a

✍ Papamlchael, D.; Penson, R.T.; Seymour, M.T.; Wilson, P.; Gallagher, C.J.; Besse 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 266 KB